BACKGROUND: The objective of this study was to identify trends and predictors of the time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). METHODS: The National Cancer Database (NCDB) was reviewed for the following head and neck cancer sites: oral tongue, oropharynx, larynx, and hypopharynx. TTI was defined as the number of days from diagnosis to the initiation of definitive treatment and was measured according to covariates. Significant differences in the median TTI across each covariate were measured using the Kruskal-Wallis test, and the Spearman test was used to measure trends within covariates. For multivariate analysis, a zero-inflated, negative, binomial regression model was used to estimate the expected TTI, which was expressed in the predicted number of days; and the Vuong test was used to identify the predictors of TTI. RESULTS: In total, 274,630 patients were included. Between 1998 and 2011, the median TTI for all patients was 26 days, and it increased from 19 days to 30 days (P < .0001). Treatment with chemoradiation (CRT) (P < .0001), treatment at academic facilities (P < .0001), and stage IV disease (P < .0001) were associated with increased TTI. TTI significantly increased for each disease stage (P < .0001), treatment modality (P < .0001), and facility type (P < .0001) over time. In addition, patients became more likely to transition care between facilities after diagnosis for treatment initiation (P < .0001) over time. On multivariate analysis, treatment at academic facilities (33 days), transitioning care (37 days), and receipt of CRT (39 days) predicted for a longer TTI. CONCLUSIONS: TTI is rising for patients with HNSCC. Those who have advanced-stage disease, receive treatment with CRT, are treated at academic facilities, and who have a transition in care realized the greatest increases in TTI.
BACKGROUND: The objective of this study was to identify trends and predictors of the time to treatment initiation (TTI) for patients with head and neck squamous cell carcinoma (HNSCC). METHODS: The National Cancer Database (NCDB) was reviewed for the following head and neck cancer sites: oral tongue, oropharynx, larynx, and hypopharynx. TTI was defined as the number of days from diagnosis to the initiation of definitive treatment and was measured according to covariates. Significant differences in the median TTI across each covariate were measured using the Kruskal-Wallis test, and the Spearman test was used to measure trends within covariates. For multivariate analysis, a zero-inflated, negative, binomial regression model was used to estimate the expected TTI, which was expressed in the predicted number of days; and the Vuong test was used to identify the predictors of TTI. RESULTS: In total, 274,630 patients were included. Between 1998 and 2011, the median TTI for all patients was 26 days, and it increased from 19 days to 30 days (P < .0001). Treatment with chemoradiation (CRT) (P < .0001), treatment at academic facilities (P < .0001), and stage IV disease (P < .0001) were associated with increased TTI. TTI significantly increased for each disease stage (P < .0001), treatment modality (P < .0001), and facility type (P < .0001) over time. In addition, patients became more likely to transition care between facilities after diagnosis for treatment initiation (P < .0001) over time. On multivariate analysis, treatment at academic facilities (33 days), transitioning care (37 days), and receipt of CRT (39 days) predicted for a longer TTI. CONCLUSIONS: TTI is rising for patients with HNSCC. Those who have advanced-stage disease, receive treatment with CRT, are treated at academic facilities, and who have a transition in care realized the greatest increases in TTI.
Authors: Luke H DeGraaff; Alexis J Platek; Austin J Iovoli; Kimberly E Wooten; Hassan Arshad; Vishal Gupta; Ryan P McSpadden; Moni Abraham Kuriakose; Wesley L Hicks; Mary E Platek; Anurag K Singh Journal: Oral Oncol Date: 2019-07-30 Impact factor: 5.337
Authors: Roy Xiao; Rohan R Joshi; Qasim Husain; Jennifer R Cracchiolo; Nancy Lee; Jillian Tsai; Yao Yu; Linda Chen; Jung J Kang; Sean McBride; Nadeem Riaz; Benjamin R Roman; Ian Ganly; Viviane Tabar; Stacey T Gray; Marc A Cohen Journal: Head Neck Date: 2019-07-11 Impact factor: 3.147
Authors: Chandler J Rygalski; Songzhu Zhao; Antoine Eskander; Sidharth V Puram; Stephen Y Kang Journal: Ann Surg Oncol Date: 2020-11-13 Impact factor: 5.344
Authors: Stephan Kruger; Karoline Schirle; Michael Haas; Alexander Crispin; Jörg Schirra; Julia Mayerle; Jan G D'Haese; Wolfgang G Kunz; Jens Ricke; Steffen Ormanns; Thomas Kirchner; Sebastian Kobold; Matthias Ilmer; Leonie Gebauer; Christoph B Westphalen; Michael von Bergwelt-Baildon; Jens Werner; Volker Heinemann; Stefan Boeck Journal: J Cancer Res Clin Oncol Date: 2019-10-23 Impact factor: 4.553
Authors: Colin T Murphy; Thomas J Galloway; Elizabeth A Handorf; Brian L Egleston; Lora S Wang; Ranee Mehra; Douglas B Flieder; John A Ridge Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Talha Shaikh; Elizabeth A Handorf; Colin T Murphy; Ranee Mehra; John A Ridge; Thomas J Galloway Journal: Int J Radiat Oncol Biol Phys Date: 2016-09-06 Impact factor: 7.038
Authors: A Andreano; M Ansarin; D Alterio; R Bruschini; M G Valsecchi; A G Russo Journal: Acta Otorhinolaryngol Ital Date: 2018-02 Impact factor: 2.124
Authors: Tyler A Janz; Joanne Kim; Elizabeth G Hill; Katherine Sterba; Graham Warren; Anand K Sharma; Terry A Day; Chanita Hughes-Halbert; Evan M Graboyes Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-12-01 Impact factor: 6.223